The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.

Adult Aged Biomarkers, Tumor Cell Transformation, Viral Epstein-Barr Virus Infections / etiology Gene Expression Herpesvirus 4, Human / genetics Humans Immune Tolerance Kaplan-Meier Estimate Lymphoma, Large B-Cell, Diffuse / etiology Middle Aged Neoplasm Staging Prognosis Tumor Microenvironment / immunology
Epstein-Barr virus diffuse large B-cell lymphoma immune checkpoints tumour microenvironment tumour-associated macrophages

Journal

European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 18 03 2019
revised: 04 06 2019
accepted: 06 06 2019
pubmed: 19 6 2019
medline: 25 1 2020
entrez: 19 6 2019
Statut: ppublish

Résumé

Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV We used the NanoString™ platform in a population-based cohort of 433 patients to establish if the technology could detect EBV in the tumour biopsies and to investigate the influence that EBV has on the complex tumour microenvironment of DLBCL. Incidence of EBV In EBV

Identifiants

DOI: 10.1111/ejh.13274 PMID: 31211907 PMC: PMC6899834
pubmed: 31211907
doi: 10.1111/ejh.13274
pmc: PMC6899834
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

200-207

Subventions

Organisme : Kasey-Anne Lymphoma Giving Fund
Organisme : Lord Mayor's Charitable Foundation
Organisme : Pathology Queensland Study, Education and Research Committee
Organisme : Education and Research Committee
Organisme : Leukaemia Foundation Bridgestone Award
Organisme : NHMRC Early Career Fellowship
Organisme : Haematology Society of Australia and New Zealand New Investigator Award
Organisme : Cancer Australia
Organisme : Cancer Cure Australia

Informations de copyright

© 2019 The Authors European Journal of Haematology Published by John Wiley & Sons Ltd.

Références

Mod Pathol. 2011 Aug;24(8):1046-54
pubmed: 21499229
Expert Rev Anti Infect Ther. 2006 Feb;4(1):77-89
pubmed: 16441211
Clin Cancer Res. 2007 Sep 1;13(17):5124-32
pubmed: 17785567
Haematologica. 2016 May;101(5):531-40
pubmed: 27132279
Am J Hematol. 2013 Sep;88(9):774-9
pubmed: 23760676
Eur J Haematol. 2019 Sep;103(3):200-207
pubmed: 31211907
Blood. 2018 Apr 19;131(16):1809-1819
pubmed: 29449276
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Hum Pathol. 2010 Mar;41(3):352-7
pubmed: 19913281
Oncotarget. 2015 Jun 10;6(16):13933-45
pubmed: 26101854
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893938
Biochim Biophys Acta. 2016 Mar;1863(3):471-482
pubmed: 26554850
Am J Transplant. 2011 May;11(5):888-95
pubmed: 21521464
Sci Rep. 2015 Jul 23;5:12168
pubmed: 26202875
Clin Cancer Res. 2012 Mar 15;18(6):1611-8
pubmed: 22271878
Leuk Res. 2012 Apr;36(4):413-7
pubmed: 22277681
Blood. 1998 Aug 1;92(3):1020-30
pubmed: 9680372
Blood. 2015 Aug 13;126(7):863-72
pubmed: 25999451
Blood. 2013 Jul 18;122(3):328-40
pubmed: 23649469
Oncotarget. 2017 Mar 28;8(13):22014-22022
pubmed: 28423544
Blood. 2010 Sep 30;116(13):2245-52
pubmed: 20562330
Blood. 2014 Feb 20;123(8):1214-7
pubmed: 24398326
Clin Cancer Res. 2013 Feb 1;19(3):731-42
pubmed: 23224400
Leukemia. 2012 Jan;26(1):180-3
pubmed: 21788950
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
pubmed: 12900505
Haematologica. 2018 Feb;103(2):297-303
pubmed: 29170255
Clin Cancer Res. 2017 Apr 1;23(7):1820-1828
pubmed: 27649554
Ann Oncol. 2015 Mar;26(3):548-55
pubmed: 25475080
Cancer Sci. 2014 Sep;105(9):1170-5
pubmed: 24974976
Lancet Haematol. 2015 Oct;2(10):e445-55
pubmed: 26686046
Blood. 2006 Oct 1;108(7):2280-9
pubmed: 16757686
Jpn J Cancer Res. 2000 Dec;91(12):1233-40
pubmed: 11123421
Annu Rev Immunol. 2007;25:587-617
pubmed: 17378764
Am J Hematol. 2013 Apr;88(4):273-6
pubmed: 23460351
N Engl J Med. 2004 Mar 25;350(13):1328-37
pubmed: 15044644
Clin Cancer Res. 2014 May 1;20(9):2338-49
pubmed: 24583797
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
pubmed: 23674495
J Virol Methods. 2012 Sep;184(1-2):46-54
pubmed: 22609801
Clin Exp Immunol. 2016 Feb;183(2):206-20
pubmed: 26422112
Hematol Oncol. 2018 Feb;36(1):93-97
pubmed: 28639256
Blood. 1998 Oct 1;92(7):2477-83
pubmed: 9746788
Blood. 2007 Aug 1;110(3):972-8
pubmed: 17400912
Nat Rev Cancer. 2014 Aug;14(8):517-34
pubmed: 25008267

Auteurs

Colm Keane (C)

Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Princess Alexandra Hospital, Brisbane, Queensland, Australia.
ORCID: 0000-0002-9009-9934

Joshua Tobin (J)

Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Jay Gunawardana (J)

Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.

Santiyagu Francis (S)

Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.

Grace Gifford (G)

Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Sara Gabrielli (S)

Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.

Anthony Gill (A)

Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

William Stevenson (W)

Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Dipti Talaulikar (D)

Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Australia National University Medical School, Canberra, Australian Capital Territory, Australia.

Clare Gould (C)

Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Sanjiv Jain (S)

Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Australia National University Medical School, Canberra, Australian Capital Territory, Australia.

Simone Birch (S)

Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Pathology Queensland, Brisbane, Queensland, Australia.

Mark Hertzberg (M)

Prince of Wales Hospital, Sydney, New South Wales, Australia.

Maher K Gandhi (MK)

Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › The tumour microenvironment is...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › The tumour microenvironment is...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › The tumour microenvironment is...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Transformation cellulaire virale › The tumour microenvironment is...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus oncogènes › Infections à virus Epstein-Barr › The tumour microenvironment is...
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › The tumour microenvironment is...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Gammaherpesvirinae › Lymphocryptovirus › Herpèsvirus humain de type 4 › The tumour microenvironment is...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The tumour microenvironment is...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Tolérance immunitaire › The tumour microenvironment is...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Estimation de Kaplan-Meier › The tumour microenvironment is...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B diffus à grandes cellules › The tumour microenvironment is...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › The tumour microenvironment is...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › The tumour microenvironment is...
questionsmedicales.fr › Diagnostic › Pronostic › The tumour microenvironment is...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › The tumour microenvironment is...